Plasma L-Carnitine and L-Lysine Concentrations in HIV-Infected Patients

Table 2: Plasma L-carnitine and L-lysine concentrations in HIV-infected patients (group I, II, III) and controls (comparison group 1, 2).

	HIV Infection Stage (CDC, 1993)			Controls
	HIV Infection Stage (CDC, 1993)			Comparison Group 1 (HIV-infected subjects under HAART) (n=125)	Comparison Group 2 (healthy donors) (n=140)
	Group I (A1, A2) (n= 240)	Group II (B2, B2) (n=130)	Group III (C1, C2) (n=60)		Comparison Group 2 (healthy donors) (n=140)
Total carnitine (TC) (μmol/l)	33.1±7.8^●	29.4±7.7^●	26.1±5.8^●	25.7±4.4″	46.3±5.1^●″
Free carnitine (FC) (µmol/l)	23.0±5.2^●	19.2±5.1^●	16.5±4.9^●	16.2±5.4″	34.1±4.8^●″
L-lysine (µmol/l)	253.1±144.9	212.3±135.0*^●	149.1±110.5*^●	283.0±142.7*	275.8±120.3^●

* Patients without HAART versus comparison group 1, P < 0.05 or less
^● Patients without HAART versus comparison group 2, P < 0.05 or less
″ Patients under HAART versus comparison group 2, P < 0.05 or less
Values are given as mean±s.d.